SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9803)5/6/1999 1:16:00 AM
From: aknahow  Respond to of 17367
 
I actually think they will hit the number. It is almost two months since Castello said they were close. I think close meant two or at most three more deaths. Think 15 accruals minimum were added since then and that this makes objective obtainable.



To: Bluegreen who wrote (9803)5/6/1999 8:59:00 AM
From: Robert K.  Read Replies (2) | Respond to of 17367
 
I would like to remind everyone that natural bpi DOES work in vivo in
EACH of us right now. The real question is if rbpi is good enough and can find clinical utility. I venture a guess that the question has generally been answered on the good enough issue. That would leave us with the clinical utility issue. Thats where we are now.
Standard K disclaimers.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News